A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL

In the postrituximab era, approximately half of the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response to standard salvage therapy, and are thus ineligible to proceed to autologous stem cell transplantation with curative int...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Sauter, Craig S., Matasar, Matthew J., Schoder, Heiko, Devlin, Sean M., Drullinsky, Pamela, Gerecitano, John, Kumar, Anita, Noy, Ariela, Palomba, Maria L., Portlock, Carol S., Straus, David J., Zelenetz, Andrew D., McCall, Susan J., Miller, Shoshana T., Courtien, Amanda I., Younes, Anas, Moskowitz, Craig H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5909762/
https://ncbi.nlm.nih.gov/pubmed/29386196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-08-802561
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados